In silico mediated development of orthogonally selective mAb downstream processes for the removal of process-related impurities.

Continued advancements in recombinant CHO expression of therapeutic mAbs have led to improved productivity but have also increased the HCP burden on the downstream purification process. In this work, we developed an in silico mediated workflow to fac…

Preview only. Read the full abstract at the source